Simple Score to Predict Treatment Response to Low-Dose Tolvaptan in Patients with Heart Failure
Open Access
- 30 March 2022
- journal article
- research article
- Published by International Heart Journal (Japanese Heart Journal) in International Heart Journal
- Vol. 63 (2) , 247-254
Abstract
The recommended starting dose of Tolvaptan for heart failure (HF) is 7.5 mg/day in Japan; the recommended dose is 3.75 mg/day for older patients to avoid excessive diuresis and hypernatremia. However, low-dose Tolvaptan may delay the release of congestion in some patients. We aimed to develop a score to predict treatment responders to 3.75 mg tolvaptan.We retrospectively analyzed 106 patients with HF who initially received 3.75 mg/day of Tolvaptan in the derivation cohort (April 2013-December 2017) and 63 patients receiving 3.75 mg/day of Tolvaptan in the validation cohort (January 2018-April 2021). Treatment responders to 3.75 mg tolvaptan did not require dose escalation of Tolvaptan for congestion relief. In multivariate analysis, blood urea nitrogen (BUN) < 39 mg/dL and hematocrit > 35% were selected as variables to predict treatment responders. These were assigned 1 point each, and patients were stratified into groups with 2 points (n = 32), 1 point (n = 39), and 0 points (n = 35). The frequency of treatment responders was 82.9% in the 2-point group, 61.5% in the 1-point group, and 34.4% in the 0-point group (P < 0.05). The predictive ability of the score was acceptable with an area under the receiving operator characteristic curve (AUC) 0.726 (P < 0.05); its performance was maintained in the validation cohort (AUC 0.733, P < 0.05).A simple score using BUN and hematocrit could identify treatment responders to 3.75 mg tolvaptan, which may help determine the appropriate starting dose of Tolvaptan, balancing efficiency with safety for older patients with HF.Keywords
This publication has 14 references indexed in Scilit:
- Cardiorenal Syndrome and Heart Failure—Challenges and OpportunitiesCanadian Journal of Cardiology, 2019
- Ultrasound Assessment of Kidney Volume in Patients with Acute Decompensated Heart Failure: A Predictor of Diuretic ResistanceYonago Acta Medica, 2017
- Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failureHeart and Vessels, 2015
- Efficacy and Safety of Tolvaptan in Heart Failure Patients With Volume OverloadCirculation Journal, 2014
- Geriatric Nutritional Risk Index Predicts Functional Dependency and Mortality in Patients With Heart Failure With Preserved Ejection FractionCirculation Journal, 2013
- Emergence of Blood Urea Nitrogen as a Biomarker of Neurohormonal Activation in Heart FailureThe American Journal of Cardiology, 2010
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status TrialsJAMA, 2007
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007
- Rationale and Design of a Randomized Trial to Assess the Effects of Diuretics in Heart Failure Japanese Multicenter Evaluation of Long- vs Short-Acting Diuretics in Congestive Heart Failure (J-MELODIC)Circulation Journal, 2007
- Hemodilution Is Common in Patients With Advanced Heart FailureCirculation, 2003